Literature DB >> 18306483

Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.

Kwang Min Kim1, Ho-Cheol Kim, Kyung-Nyeo Jeon, Hoon-Gu Kim, Jung Hun Kang, Jong Ryeal Hahm, Gyeong-Won Lee.   

Abstract

A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18306483      PMCID： PMC2615269          DOI： 10.3349/ymj.2008.49.1.155

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN： 0513-5796            Impact factor:   2.759


  25 in total

1.  Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.

Authors:  R Soda; A Costanzo; M Cantonetti; A Orlandi; L Bianchi; S Chimenti
Journal:  Acta Derm Venereol       Date:  2001 Jun-Jul       Impact factor: 4.437

2.  Interstitial pneumonitis related to rituximab therapy.

Authors:  Catherine Burton; Richard Kaczmarski; Riaz Jan-Mohamed
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

3.  Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease.

Authors:  Shahid Ahmed; Steven J Kussick; Anita K Siddiqui; Tawfiqul A Bhuiya; Arfa Khan; Stephen Sarewitz; Harry Steinberg; Cristina P Sison; Kanti R Rai
Journal:  Eur J Cancer       Date:  2004-06       Impact factor: 9.162

4.  Docetaxel and interstitial pulmonary injury.

Authors:  M Merad; A Le Cesne; P Baldeyrou; B Mesurolle; T Le Chevalier
Journal:  Ann Oncol       Date:  1997-02       Impact factor: 32.976

Review 5.  Rituximab: mechanism of action and resistance.

Authors:  David G Maloney; Barbara Smith; Andrea Rose
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

6.  Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis.

Authors:  S Kanelli; S M Ansell; T M Habermann; D J Inwards; N Tuinstra; T E Witzig
Journal:  Leuk Lymphoma       Date:  2001 Nov-Dec

7.  Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.

Authors:  Doru T Alexandrescu; Janice P Dutcher; Kevin O'Boyle; Mehmet Albulak; Stanley Oiseth; Peter H Wiernik
Journal:  Leuk Lymphoma       Date:  2004-11

8.  First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.

Authors:  John D Hainsworth; Sharlene Litchy; M Ray Lamb; Gladys I Rodriguez; Carroll Scroggin; F Anthony Greco
Journal:  Clin Lymphoma       Date:  2003-06

9.  Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

Authors:  Annarita Conconi; Giovanni Martinelli; Catherine Thiéblemont; Andrés J M Ferreri; Liliana Devizzi; Fedro Peccatori; Maurilio Ponzoni; Ennio Pedrinis; Stefania Dell'Oro; Giancarlo Pruneri; Virginio Filipazzi; Pierre-Yves Dietrich; Alessandro M Gianni; Bertrand Coiffier; Franco Cavalli; Emanuele Zucca
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

10.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors:  John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113
View more
  6 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

2.  Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan.

Authors:  Moon Jin Kim; Gyeong-Won Lee; Jong Woo Seo; Hyun-Jung Kim; Sung-Nam Lim; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2010-05-21       Impact factor: 3.850

3.  Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.

Authors:  Kanako Inaba; Takahide Arimoto; Mari Hoya; Kei Kawana; Shunsuke Nakagawa; Shiro Kozuma; Yuji Taketani
Journal:  Med Oncol       Date:  2011-03-10       Impact factor: 3.064

4.  Rituximab-induced bronchiolitis obliterans organizing pneumonia.

Authors:  Ahmet B Ergin; Nancy Fong; Hamed A Daw
Journal:  Case Rep Med       Date:  2012-06-19

5.  Human leptin protein induces proliferation of A549 cells via inhibition of PKR-like ER kinase and activating transcription factor-6 mediated apoptosis.

Authors:  Qun Lai; Yan Sun
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

6.  A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Authors:  Paraskevi Fragkou; Maria Souli; Maria Theochari; Christina Kontopoulou; Stelios Loukides; Anna Koumarianou
Journal:  Drug Target Insights       Date:  2016-05-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.